



FOR RELEASE
September 12, 2006

Contacts: Rob Stewart
Investor Relations
Tel (949) 480-8300
Fax (949) 480-8301

ACACIA TECHNOLOGIES ACQUIRES RIGHTS TO PATENTS FOR MEDICAL IMAGE STABILIZATION TECHNOLOGY

Newport Beach, CA. – (BUSINESS WIRE) September 12, 2006 – Acacia Research Corporation (Nasdaq: ACTG: CBMX) announced today that Acacia Patent Acquisition Corporation, a wholly owned subsidiary that is part of the Acacia Technologies group, a leader in technology licensing, has acquired rights to a patent portfolio relating to imaging technology that aids medical personnel in the examination of patients.

“Acacia is serving an unmet need in the market for companies that want to generate revenue from the licensing of their patented technologies. Acacia’s licensing success is attracting more companies that are selecting us as their partner,” commented Paul Ryan, Acacia Chairman and CEO. “We now control 48 patent portfolios,” concluded Mr. Ryan.

This technology can be used in stabilizing medical images for interventional procedures such as cardiac catheters and stents, and for diagnostic procedures such as visualization of arterial lesions.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 48 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.